Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome-Reference-Cited by-同舟云学术

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

Published:2021-08-02 Issue:3 Volume:195 Page:378-387
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chien Kelly S.¹^ORCID,Kim Kunhwa¹,Nogueras‐Gonzalez Graciela M.²,Borthakur Gautam¹^ORCID,Naqvi Kiran¹,Daver Naval G.¹^ORCID,Montalban‐Bravo Guillermo¹^ORCID,Cortes Jorge E.¹^ORCID,DiNardo Courtney D.¹,Jabbour Elias¹,Alvarado Yesid¹,Andreeff Michael¹,Bose Prithviraj¹,Jain Nitin¹^ORCID,Kadia Tapan M.¹,Huang Xuelin²,Sheppard Kimberly B.¹,Klingner‐Winton Cheri¹,Pierce Sherry A.¹,Dong Xiao Qin¹,Soltysiak Kelly A.¹,Kantarjian Hagop M.¹,Garcia‐Manero Guillermo¹^ORCID

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA

2. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston TX USA

Funder

Merck

University of Texas MD Anderson Cancer Center

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17689